Literature DB >> 26639775

Regadenoson stress for myocardial perfusion imaging.

Eliana Reyes1,2.   

Abstract

Noninvasive functional imaging plays a major role in the diagnosis of hemodynamically significant coronary artery disease (CAD) by means of the detection of abnormal myocardial perfusion. For this, cardiac stressors are essential as they induce hypoperfusion in the presence of flow-limiting coronary stenosis. Several pharmacological stressors are currently available and it is important that clinicians who are involved in the care and management of patients with CAD become familiar with their indications, contraindications and protocols. Among the primary coronary vasodilator agents, regadenoson is increasingly used as the default stressor or as an alternative to other modalities of stress. This article provides an updated review of regadenoson stress for the assessment of patients with suspected or known CAD and describes its pharmacological properties, stress protocol, efficacy and safety profile.

Entities:  

Keywords:  coronary artery disease; myocardial perfusion imaging; regadenoson

Mesh:

Substances:

Year:  2015        PMID: 26639775     DOI: 10.2217/fca.15.70

Source DB:  PubMed          Journal:  Future Cardiol        ISSN: 1479-6678


  3 in total

Review 1.  Pharmacological Activity and Clinical Use of PDRN.

Authors:  Francesco Squadrito; Alessandra Bitto; Natasha Irrera; Gabriele Pizzino; Giovanni Pallio; Letteria Minutoli; Domenica Altavilla
Journal:  Front Pharmacol       Date:  2017-04-26       Impact factor: 5.810

2.  Regadenoson myocardial perfusion scintigraphy for the evaluation of coronary artery disease in patients with lung disease: A series of five cases.

Authors:  Eliana Reyes; Stephen Richard Underwood
Journal:  J Nucl Cardiol       Date:  2019-12-03       Impact factor: 5.952

3.  Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y12 Receptor Antagonists.

Authors:  Nina Wolska; Magdalena Boncler; Dawid Polak; Joanna Wzorek; Tomasz Przygodzki; Magdalena Gapinska; Cezary Watala; Marcin Rozalski
Journal:  Molecules       Date:  2019-12-28       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.